OUR COMPANIES / Life Sciences

Adamas

www.adamaspharma.com
Board Members: Bill Ericson
Initiatives: Life Sciences
Ticker: Private

Advantaged Therapeutics for Global Health^™

Adamas is an emerging pharmaceutical company focused on developing small molecule Advantaged Therapeutics to treat neurological and infectious diseases, including influenza A, the cause of the current flu pandemic. Adamas’ approach to product development is to identify unmet needs where existing drugs can be developed as optimized combination drug therapies to increase safety, efficacy and compliance, thus improving upon the standard of care. Adamas is headquartered in Emeryville, California, with operations in Bangalore, India.

Facts & Statistics

Over 6 million people in the U.S. suffer from chronic neurodegenerative diseases such as dementia and Parkinson’s disease.
Adamas is developing Advantaged Therapeutics for dementia and Parkinson’s disease that are designed to provide improved efficacy and tolerability and to simplify daily drug regimens.
Each year in the U.S. Over 36,000 people die from influenza-related complications and more than 200,000 people are hospitalized from influenza-related causes.
Adamas is developing a proprietary triple combination antiviral drug (TCAD) therapy as a broad spectrum anti-influenza treatment to overcome drug resistance as well as the known limitations of influenza monotherapy.

Mohr Davidow

INITIATIVES

All Companies

OUR COMPANIES / Life Sciences

Adamas

Facts & Statistics